TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Visual abstract | Key updates to the classification of MPN in the 5th WHO Classification of Haematolymphoid Tumours

Sep 21, 2022

Learning objective: After reading this article, learners will be able to recall key changes in the classification of myeloproliferative neoplasms and mastocytosis from the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours.


The MPN Hub is pleased to present a visual abstract highlighting key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Updates are focused on the changes in the rationale behind the classification of myeloproliferative neoplasms and mastocytosis, focusing on combined morphologic, immunophenotypic, molecular, and cytogenetic data that help to refine diagnostic criteria and emphasize therapeutically and/or prognostically actionable biomarkers.


 

Visual Abstract

To download this visual abstract, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content